Sonoma Pharmaceuticals Files 8-K
Ticker: SNOA · Form: 8-K · Filed: Sep 26, 2025 · CIK: 1367083
Sentiment: neutral
Topics: material-definitive-agreement, financial-statements, exhibits
Related Tickers: SONM
TL;DR
Sonoma Pharma (SONM) filed an 8-K on 9/26/25 - new deal or financials incoming.
AI Summary
Sonoma Pharmaceuticals, Inc. filed an 8-K on September 26, 2025, reporting the entry into a material definitive agreement and the filing of financial statements and exhibits. The company, formerly known as Oculus Innovative Sciences, Inc., is headquartered in Boulder, Colorado.
Why It Matters
This filing indicates significant corporate activity, potentially involving new agreements or updated financial information that could impact investors.
Risk Assessment
Risk Level: low — This is a routine 8-K filing indicating corporate actions, not a direct financial event or negative news.
Key Players & Entities
- Sonoma Pharmaceuticals, Inc. (company) — Registrant
- September 26, 2025 (date) — Date of earliest event reported
- Oculus Innovative Sciences, Inc. (company) — Former company name
- Boulder, CO (location) — Principal executive offices address
FAQ
What specific material definitive agreement was entered into by Sonoma Pharmaceuticals, Inc. on or before September 26, 2025?
The filing does not specify the details of the material definitive agreement, only that one was entered into.
What financial statements and exhibits are being filed with this 8-K?
The filing indicates that financial statements and exhibits are being filed, but their specific content is not detailed in the provided excerpt.
When was Sonoma Pharmaceuticals, Inc. formerly known as Oculus Innovative Sciences, Inc.?
The company's name change from Oculus Innovative Sciences, Inc. to Sonoma Pharmaceuticals, Inc. occurred on June 22, 2006.
What is the principal executive office address for Sonoma Pharmaceuticals, Inc.?
The principal executive offices are located at 5445 Conestoga Court, Suite 150, Boulder, CO 80301.
What is the IRS Employer Identification Number (EIN) for Sonoma Pharmaceuticals, Inc.?
The EIN for Sonoma Pharmaceuticals, Inc. is 68-0423298.
Filing Stats: 1,094 words · 4 min read · ~4 pages · Grade level 11.5 · Accepted 2025-09-26 17:01:36
Key Financial Figures
- $0.0001 — , as agent, shares of its common stock, $0.0001 par value per share. Subject to the te
- $40,000 — for certain specified expenses of up to $40,000. The Company is not obligated to make
- $2,070,463 — or an aggregate offering price of up to $2,070,463. The foregoing summary of the Agreemen
Filing Documents
- sonoma_8k.htm (8-K) — 32KB
- sonoma_ex0101.htm (EX-1.1) — 278KB
- sonoma_ex0501.htm (EX-5.1) — 11KB
- image_001.jpg (GRAPHIC) — 5KB
- 0001683168-25-007265.txt ( ) — 561KB
- snoa-20250926.xsd (EX-101.SCH) — 3KB
- snoa-20250926_lab.xml (EX-101.LAB) — 33KB
- snoa-20250926_pre.xml (EX-101.PRE) — 22KB
- sonoma_8k_htm.xml (XML) — 4KB
01 Entry into a Material Definitive
Item 1.01 Entry into a Material Definitive Agreement. On September 26, 2025, Sonoma Pharmaceuticals, Inc. (the "Company") entered into an At Market Issuance Sales Agreement (the "Agreement"), with Ladenburg Thalmann & Co. Inc. ("Ladenburg"), pursuant to which the Company may offer and sell, from time to time, through Ladenburg, as agent, shares of its common stock, $0.0001 par value per share. use commercially reasonable efforts consistent with its normal trading and sales practices, applicable state and federal law, rules and regulations and the rules of the Nasdaq Capital Market to sell shares from time to time based upon the Company's instructions, including any price, time or size limits specified by the Company. Under the Agreement, Ladenburg may sell shares by any method deemed to be an "at the market" offering as defined in Rule 415 under the U.S. Securities Act of 1933, as amended, or any other method permitted by law, including in privately negotiated transactions. Ladenburg's obligations to sell shares under the Agreement are subject to satisfaction of certain conditions, including customary closing conditions for transactions of this nature. The Company will pay Ladenburg a commission of 3% of the aggregate gross proceeds from each sale of shares and has agreed to provide Ladenburg with customary indemnification and contribution rights. The Company also agreed to reimburse Ladenburg for certain specified expenses of up to $40,000. The Company is not obligated to make any sales of its common stock under the Agreement and no assurance can be given that the Company will sell any shares under the Agreement, or, if it does, as to the price or amount of shares that the Company will sell, or the dates on which any such sales will take place. The Agreement will terminate upon the earlier of (i) the sale of all shares under the Agreement, or (ii) as provided therein. Sales of shares of commo
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 1.1 At Market Issuance Sales Agreement, by and between the Company and Ladenburg Thalmann & Co. Inc., dated September 26, 2025. 5.1 Opinion of Polsinelli PC. 23.1 Consent of Polsinelli PC (included in Exhibit 5.1 ). 104 Cover Page Interactive Data File (formatted in Inline XBRL in Exhibit 101). ___________________
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SONOMA PHARMACEUTICALS, INC. Date: September 26, 2025 By: /s/ Amy Trombly Name: Title: Amy Trombly Chief Executive Officer 2